EXACT Therapeutics - Annual Report 2025
Oslo, 09 April 2026: Please find enclosed the 2025 Annual Report for Exact Therapeutics AS.
For further information, please contact:
Per Walday CEO EXACT Therapeutics Email: per.walday@exact-tx.com
John M. Edminson CFO EXACT Therapeutics Email: john.edminson@exact-tx.com
About EXACT Therapeutics: EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com